

Roman Prymula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7931408/publications.pdf>

Version: 2024-02-01

37
papers

2,591
citations

304368

22
h-index

329751

37
g-index

39
all docs

39
docs citations

39
times ranked

2501
citing authors

#	ARTICLE	IF	CITATIONS
1	Five Antigen Tests for SARS-CoV-2: Virus Viability Matters. <i>Viruses</i> , 2021, 13, 684.	1.5	29
2	Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries. <i>Vaccine</i> , 2021, 39, 2643-2651.	1.7	7
3	Covid-19 antigen testing: better than we know? A test accuracy study. <i>Infectious Diseases</i> , 2021, 53, 661-668.	1.4	14
4	Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants. <i>Vaccine</i> , 2021, 39, 3445-3454.	1.7	7
5	Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e1-e10.	1.1	23
6	Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. <i>Frontiers in Immunology</i> , 2020, 11, 1282.	2.2	68
7	Complex Reporting of the COVID-19 Epidemic in the Czech Republic: Use of an Interactive Web-Based App in Practice. <i>Journal of Medical Internet Research</i> , 2020, 22, e19367.	2.1	53
8	Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study. <i>Vaccine</i> , 2019, 37, 176-186.	1.7	13
9	Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 287-297.	4.6	33
10	Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 203-210.	1.1	2
11	Vaccination in newly arrived immigrants to the European Union. <i>Vaccine</i> , 2018, 36, 5385-5390.	1.7	7
12	Influenza vaccination in the elderly. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 540-549.	1.4	110
13	Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age—a phase 3 extension to a randomised controlled trial. <i>Vaccine</i> , 2017, 35, 395-402.	1.7	19
14	Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants. <i>Vaccine</i> , 2017, 35, 4603-4611.	1.7	26
15	Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. <i>Vaccine</i> , 2017, 35, 5186-5193.	1.7	16
16	Comparative Epidemiologic Characteristics of Pertussis in 10 Central and Eastern European Countries, 2000-2013. <i>PLoS ONE</i> , 2016, 11, e0155949.	1.1	45
17	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-18.	1.4	49
18	Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial. <i>BMC Pediatrics</i> , 2016, 16, 7.	0.7	9

#	ARTICLE	IF	CITATIONS
19	How can we improve compliance with vaccination in Europe?. <i>Future Microbiology</i> , 2015, 10, 1397-1400.	1.0	1
20	Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. <i>Vaccine</i> , 2015, 33, 3850-3858.	1.7	19
21	A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1993-2004.	1.4	81
22	A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2005-2014.	1.4	37
23	A repeated syphilis infection imported from Thailand in an HIV positive couple of men-who-have-sex-with-men in Czech Republic. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 84-87.	1.5	5
24	Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial. <i>Vaccine</i> , 2014, 32, 3025-3034.	1.7	52
25	Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. <i>Lancet, The</i> , 2014, 383, 1313-1324.	6.3	83
26	Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. <i>Vaccine</i> , 2013, 31, 2080-2088.	1.7	37
27	Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. <i>Lancet, The</i> , 2013, 381, 825-835.	6.3	247
28	Controversies in Vaccination. <i>European Review</i> , 2013, 21, S56-S61.	0.4	3
29	Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in Adults. Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults. <i>Central European Journal of Public Health</i> , 2013, 21, 233-236.	0.4	1
30	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 573-82.	3.8	247
31	Acceptance and Opinions of Intanza/IDflu Intradermal Influenza Vaccine in the Czech Republic and Turkey. <i>Advances in Therapy</i> , 2012, 29, 41-52.	1.3	22
32	Impact of the 10-valent pneumococcal non-typeable <i>Haemophilus influenzae</i> Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. <i>Vaccine</i> , 2011, 29, 1959-1967.	1.7	63
33	10-valent pneumococcal nontypeable <i>Haemophilus influenzae</i> PD conjugate vaccine: Synflorix®, € Expert Review of Vaccines, 2009, 8, 1479-1500.	2.0	130
34	Effect of vaccination with pneumococcal capsular polysaccharides conjugated to <i>Haemophilus influenzae</i> -derived protein D on nasopharyngeal carriage of <i>Streptococcus pneumoniae</i> and <i>H. influenzae</i> in children under 2 years of age. <i>Vaccine</i> , 2009, 28, 71-78.	1.7	81
35	Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet, The</i> , 2009, 374, 1339-1350.	6.3	335
36	Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable <i>Haemophilus influenzae</i> -derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, <i>Haemophilus influenzae</i> type b and control hepatitis A vaccines. <i>Vaccine</i> , 2008, 26, 4563-4570.	1.7	20

#	ARTICLE	IF	CITATIONS
37	Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both <i>Streptococcus pneumoniae</i> and non-typable <i>Haemophilus influenzae</i> : a randomised double-blind efficacy study. <i>Lancet, The</i> , 2006, 367, 740-748.	6.3	594